Does RADIUM RA-223 DICHLORIDE Cause Off label use? 68 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 68 reports of Off label use have been filed in association with RADIUM RA-223 DICHLORIDE (Xofigo). This represents 1.4% of all adverse event reports for RADIUM RA-223 DICHLORIDE.
68
Reports of Off label use with RADIUM RA-223 DICHLORIDE
1.4%
of all RADIUM RA-223 DICHLORIDE reports
21
Deaths
13
Hospitalizations
How Dangerous Is Off label use From RADIUM RA-223 DICHLORIDE?
Of the 68 reports, 21 (30.9%) resulted in death, 13 (19.1%) required hospitalization.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RADIUM RA-223 DICHLORIDE. However, 68 reports have been filed with the FAERS database.
What Other Side Effects Does RADIUM RA-223 DICHLORIDE Cause?
Prostatic specific antigen increased (449)
Hormone-refractory prostate cancer (441)
Death (376)
Anaemia (324)
Metastases to bone (315)
General physical health deterioration (308)
Fatigue (242)
Haemoglobin decreased (236)
Prostate cancer (234)
Nausea (221)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which RADIUM RA-223 DICHLORIDE Alternatives Have Lower Off label use Risk?
RADIUM RA-223 DICHLORIDE vs RALOXIFENE
RADIUM RA-223 DICHLORIDE vs RALTEGRAVIR
RADIUM RA-223 DICHLORIDE vs RALTITREXED
RADIUM RA-223 DICHLORIDE vs RAMELTEON
RADIUM RA-223 DICHLORIDE vs RAMIPRIL